focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksREDX.L Regulatory News (REDX)

  • There is currently no data for REDX

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

16 Nov 2016 15:22

RNS Number : 3730P
Redx Pharma plc
16 November 2016
 

 

 

 

 

 

 

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES

 

 

1. Identity of the issuer or the underlying issuerof existing shares to which voting rights areattached: ii

Redx Pharma plc

2 Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

X

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

 

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

 

An event changing the breakdown of voting rights

 

Other (please specify):

 

 

3. Full name of person(s) subject to thenotification obligation: iii

Alderley Park Holdings Limited

4. Full name of shareholder(s) (if different from 3.):iv

 

5. Date of the transaction and date onwhich the threshold is crossed orreached: v

21st September 2016

6. Date on which issuer notified:

15th November 2016

7. Threshold(s) that is/are crossed orreached: vi, vii

 4% to 3% Change at Direct Interest Level

      
 

 

8. Notified details:

A: Voting rights attached to shares viii, ix

Class/type ofshares

if possible usingthe ISIN CODE

Situation previousto the triggeringtransaction

Resulting situation after the triggering transaction

NumberofShares

NumberofVotingRights

Numberof shares

Number of votingrights

% of voting rights x

Direct

Direct xi

Indirect xii

Direct

Indirect

Ordinary shares of £0.01 each

3,855,084

3,855,084

3,605,084

3,605,084

 

3.9%

 

GB00BSNB6S51

 

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financialinstrument

Expirationdate xiii

Exercise/Conversion Period xiv

Number of votingrights that may beacquired if theinstrument isexercised/ converted.

% of votingrights

 

 

 

 

 

 

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi

Resulting situation after the triggering transaction

Type of financialinstrument

Exercise price

Expiration date xvii

Exercise/Conversion period xviii

Number of voting rights instrument refers to

 

% of voting rights xix, xx

 

 

 

 

 

 

 

Nominal

Delta

 

 

 

Total (A+B+C)

Number of voting rights

Percentage of voting rights

3,605,084

3.9%

                  
 

 

9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable: xxi

 

 

 

Proxy Voting:

10. Name of the proxy holder:

 

11. Number of voting rights proxy holder will ceaseto hold:

 

12. Date on which proxy holder will cease to holdvoting rights:

 

 

13. Additional information:

 

14. Contact name:

Andy Allan

15. Contact telephone number:

0161 232 4573

   

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLBUBDBGDBBGLL
Date   Source Headline
20th Mar 202310:38 amRNSForm 8.5 (EPT/RI)
16th Mar 20239:48 amRNSForm 8.5 (EPT/RI)
15th Mar 20234:40 pmRNSSecond Price Monitoring Extn
15th Mar 20234:35 pmRNSPrice Monitoring Extension
15th Mar 20232:05 pmRNSSecond Price Monitoring Extn
15th Mar 20232:00 pmRNSPrice Monitoring Extension
15th Mar 202310:50 amRNSStatement re: Jounce Therapeutics Press Release
14th Mar 202311:45 amRNSResult of Annual General Meeting
10th Mar 20237:00 amRNSForm 8.3 - Redx Pharma Plc
9th Mar 20234:35 pmRNSPrice Monitoring Extension
9th Mar 20232:00 pmBUSForm 8.3 - REDX PHARMA PLC
9th Mar 202311:22 amRNSForm 8 (OPD) - Jounce Therapeutics, Inc
9th Mar 202311:15 amRNSForm 8 (OPD) - Redx Pharma Plc
9th Mar 20238:34 amRNSForm 8.5 (EPT/RI)
9th Mar 20237:00 amRNSForm 8.3 - Redx Pharma plc
8th Mar 20239:05 amRNSSecond Price Monitoring Extn
8th Mar 20239:00 amRNSPrice Monitoring Extension
8th Mar 20238:38 amRNSForm 8.5 (EPT/RI)
8th Mar 20238:16 amRNSForm 8 (OPD) Jounce Therapeutics, Inc.
8th Mar 20237:00 amRNSRXC004 Topline Data From a Phase 2 Module
7th Mar 20238:30 amRNSForm 8.5 (EPT/RI)
3rd Mar 20233:08 pmRNSForm 8.3 - Jounce Therapeutics, Inc.
2nd Mar 20238:09 amRNSForm 8.5 (EPT/RI)
1st Mar 20238:48 amRNSForm 8.5 (EPT/RI)
1st Mar 20237:00 amRNSRedx to Present at Cowen Health Care Conference
28th Feb 20236:03 pmRNSForm 8.3 - Jounce Therapeutics, Inc.
27th Feb 20234:58 pmRNSForm 8.3 - Jounce Therapeutics, Inc
27th Feb 20234:47 pmRNSForm 8.3 - Redx Pharma plc
27th Feb 20234:36 pmRNSForm 8.3 - Jounce Therapeutics, Inc
27th Feb 20232:40 pmRNSForm 8.3 - Jounce Therapeutics, Inc.
27th Feb 20238:48 amRNSForm 8.5 (EPT/RI)
24th Feb 20235:18 pmRNSForm 8.3 - REDX Pharma PLC
24th Feb 20233:13 pmRNSReplacement Form 8.3 - Jounce Therapeutics, Inc.
24th Feb 20232:02 pmRNSForm 8.3 - Jounce Therapeutics, Inc.
24th Feb 202310:18 amRNSForm 8.5 (EPT/RI)
24th Feb 20237:00 amRNSForm 8.3 - Redx Pharma plc
23rd Feb 20237:15 amRNSRecommended Business Combination
23rd Feb 20237:01 amRNSRecommended Business Combination
15th Feb 20234:38 pmRNSNotice of AGM
9th Feb 20237:00 amRNSProgress Update on RXC007 Clinical Programme
23rd Jan 20237:00 amRNSRedx to Present at Wnt & ß-Catenin Pathway Summit
21st Dec 20227:00 amRNSNew Grant of Options
20th Dec 20227:00 amRNSFinal Results for the Year Ended 30 September 2022
16th Dec 20227:00 amRNSClinical Trial Agreement with MSD
13th Dec 20227:00 amRNSNotice of Preliminary Results
17th Nov 20227:00 amRNSRedx to Present Poster at IBD Nordic Conference
10th Nov 20222:00 pmRNSRXC004 Phase 2 Combination Arms to Open Enrolment
10th Nov 20227:00 amRNSRedx to Present at Jefferies London
7th Nov 20227:00 amRNSRedx Presenting at AFDD meeting
3rd Nov 20227:00 amRNSRedx to Present RXC004 Phase 1 Combination Data

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.